Magnesium sulfate as an adjuvant therapy in neonatal hypoxia

Phase 2

Active, not recruiting

• Conditions: neonatal hypoxia; hypoxic ischemic encephalopathy S100- b magnesium sulfate neonates

• Registration Number: TCTR20180720002
• Lead Sponsor: Tanta university hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-07-20
• Study Completion: 2018-08-04
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

hypoxic ischemic encephalopathy, S100-b, magnesium sulfate, neonates

Exclusion Criteria

congenital anomalies, intra uterine growth retardation (I.U.G.R), neonatal sepsis, infant of diabetic mother (I.D.M).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
hypoxia 14 days after end of the study pulse oximetry

Secondary Outcome Measures

Name	Time	Method
neonatal survival and grades of hypoxic ischemic encephalopathy 3 days our neonatal unit statistics and Sarnat staging of hypoxia